指南与共识银屑病与炎症性皮肤病湿疹皮炎与荨麻疹皮肤肿瘤

银屑病与特应性皮炎靶向治疗在恶性肿瘤背景下的SPIN-FRT推荐

Targeted therapies for psoriasis and atopic dermatitis in the context of malignancy: SPIN-FRT recommendations.
指南 / 共识 · J Eur Acad Dermatol Venereol · 2026-08-10

该指南由SPIN-FRT多学科专家组制定,综述生物制剂及口服靶向药在银屑病与特应性皮炎患者中的恶性肿瘤风险证据,并给出当前或既往恶性肿瘤及癌症风险增高患者的共识推荐。现有证据提示多数此类药物总体恶性肿瘤风险较低,但不同类别间可能存在差异,部分类别及活动性/既往恶性肿瘤患者的真实世界数据仍有限。

要点

  • 多数生物制剂及口服靶向药总体恶性肿瘤风险低,但不同类别间可能存在差异。
  • 活动性或既往恶性肿瘤患者的真实世界数据有限,需个体化权衡疾病控制与癌症风险。
  • 推荐由多学科专家共识制定,强调平衡疾病控制与潜在癌症相关风险。

核心结论

  • 现有证据提示银屑病和特应性皮炎所用多数生物制剂及口服靶向药的总体恶性肿瘤风险较低,但不同治疗类别间可能存在差异。
  • 部分治疗类别及活动性或既往恶性肿瘤患者的真实世界数据仍有限,需更多证据支持治疗决策。

研究设计与样本

  • SPIN-FRT召集的多学科专家组制定的共识推荐。
  • 基于对随机对照试验中新生恶性肿瘤风险证据及真实世界数据中癌症复发与进展证据的综述。

主要发现

  • 随机对照试验证据总结了新生恶性肿瘤风险。
  • 真实世界数据分析了生物制剂及口服靶向药治疗患者的癌症复发与进展。
  • 总体恶性肿瘤风险较低,但不同治疗类别间可能存在差异。

关键数值与推荐

  • 推荐旨在平衡疾病控制与潜在癌症相关风险,并强调关键证据缺口。

临床怎么用

  • 用于当前恶性肿瘤、既往恶性肿瘤或癌症风险增高的银屑病与特应性皮炎患者的治疗决策支持。

局限性

  • 部分治疗类别的真实世界数据有限。
  • 活动性或既往恶性肿瘤患者的真实世界数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The expanding use of biologic and oral targeted therapies has transformed the management of psoriasis and atopic dermatitis. These agents are increasingly prescribed to patients with current malignancy, a history of malignancy or an increased cancer risk, populations typically excluded from clinical trials. In the absence of robust long-term safety data, clinicians often rely on real-world evidence to inform treatment decisions. OBJECTIVES: To review the evidence regarding malignancy risk associated with biologic and oral targeted therapies used in psoriasis and atopic dermatitis and to provide expert consensus recommendations for patients with current malignancy, previous malignancy or increased risk of malignancy. METHODS: We describe the physiological roles of key immune pathways targeted in psoriasis and atopic dermatitis, as well as in cancer immunosurveillance, tumour progression and immune escape. We then summarize evidence from randomized controlled trials regarding the risk of de novo malignancy, followed by a synthesis of real-world data addressing cancer recurrence and progression in patients treated with biologic and oral targeted therapies. RESULTS: Available evidence suggests that the overall malignancy risk associated with most biologic and oral targeted therapies used in psoriasis and atopic dermatitis is low, although differences between therapeutic classes may exist. Real-world data remain limited for several therapeutic classes and in patients with active or previous malignancy. CONCLUSIONS: Based on the available evidence, we present consensus-based recommendations developed by a multidisciplinary expert panel convened by the Skin Inflammation & Psoriasis International Network-Fondation René Touraine (SPIN-FRT). These recommendations aim to support treatment decisions by balancing disease control with potential cancer-related risks while highlighting key evidence gaps.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Torres T, Brembilla NC, King B, et al. Targeted therapies for psoriasis and atopic dermatitis in the context of malignancy: SPIN-FRT recommendations. J Eur Acad Dermatol Venereol. 2026. PMID: 42573454. doi:10.1111/jdv.70634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。